Related Experiment Video
Updated: May 10, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report
Alisse Nasser1, Hosniyeh Ladadweh1, Raed Madia1
1Pharmacy Department, Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit, State of Palestine.
Background:
Dulaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is utilized for the management of type 2 diabetes and obesity, typically administered subcutaneously at a dosage of 0.75 mg/0.5 mL once weekly, with adjustments made as needed. While typically well tolerated, it may induce infrequent yet severe adverse effects, including acute pancreatitis.
Case Presentation:
In this case report, we present the first documented case of GLP-1-induced pancreatitis in Palestine. A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting. The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy. The patient experienced upper abdominal pain radiating to the back, nausea, and alternating diarrhea and constipation for 5 days. Laboratory investigations revealed elevated serum amylase and lipase levels, and imaging studies confirmed signs of acute pancreatitis. After the GLP-1 agonist was discontinued, the patient's symptoms improved, and she fully recovered.
Conclusion:
GLP-1 receptor agonists are advantageous for the management of diabetes and obesity but may precipitate acute pancreatitis in predisposed individuals. Clinicians should be aware of this potential risk and promptly investigate any patient who presents with signs of acute abdominal pain during GLP-1 therapy.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Chronic Pancreatitis I: Introduction

